



Step It Up: Best Practices for Improving SUD/OD Treatment in the Fentanyl Era

The addition of fentanyl to the nation’s drug supply has dramatically escalated overdose deaths and required providers to urgently “step up” our collective efforts to treat SUD & OUD – requiring compassion, commitment, and innovation. This conference provides prescribers and their multi-professional teams the opportunity to hear from national speakers and their colleagues and explore innovative strategies to advance our treatment efforts. Join us to hear advances on the latest practices to initiate buprenorphine and its new formulations, create contingency management programs to address stimulant use, implement peer services, partner with corrections, and more. Join your colleagues to explore how we can together step it up – it’s about saving lives.

8:00 -8:10	Overview of the day	Overview of the Day Alane OConnor, DNP
8:10 – 9:05	AM Keynote	Buprenorphine Initiations in the World of Fentanyl With the majority of the drug supply containing fentanyl, what are the strategies for high and low-dose initiations in the inpatient setting? Dr. Weinstein will explore ways to safely transition our patients onto buprenorphine, given the potential risks. She will highlight what we know and what are the directions of future research for inpatient and outpatient buprenorphine induction. Zoe Weinstein, MD, MS, Boston Chobanian & Avedisian School of Medicine
9:05– 9:15	Break	
9:15 – 9:45	Interactive Panel Discussion	Exploring the Opioid Clinical Committee’s (Opioid CAC) Guidance Documents An exploration of two Opioid CAC Guidance documents to guide our practices by panelists. <ul style="list-style-type: none"> • Ensuring Access to Medications for Opioid Use Disorder (MOUD) in Hospital Settings • <i>Draft</i> Ambulatory withdrawal and care for OUD/AUD/Other SUD Rachel Solotaroff, MD, Alane O’Connor, DNP and Kelley Harmon, DO
9:45 to 10:15	Tabletop Discussions	How do I Step it Up?

10:15 – 10:30	Transition	
10:30 – 11:30	Workshop A1	<p>Addiction Recovery Support Services: Rationale and Science</p> <p>During the past 50 years in the United States, we have learned a great deal about the causes, prevalence, clinical course, and impact of alcohol and other drug use disorders, including that these disorders tend to have a long course. Even when individuals achieve initial remission, the risk for recurrence of the disorder can remain elevated for several years. This presentation will provide a brief contextual overview of what has been learned during the past 50 years of addiction science, which has led to the emergence and growth of new models of extended recovery support services demonstrating effectiveness and cost-effectiveness in facilitating long-term remission and stable recovery.</p> <p>John Kelly, Ph.D. (pre-recorded video) and Reflective Panel</p>
	Workshop B1	<p>Partnering with Corrections</p> <p>Come learn about substance use disorder treatment in Maine jails and prisons. Presenters will review related literature as well as their own experience of successes and challenges in delivering SUD treatment in correctional settings. Presenters will also discuss successful diversion programs including pretrial/community corrections supervision rather than detention.</p> <p>Alane O’Connor, DNP, Melissa Caminiti, MPH, RN, and Elizabeth Simoni, JD</p>
	Workshop C1	<p>Ambulatory Withdrawal Management and Identifying Risk for Withdrawal</p> <p>Many patients can receive treatment for alcohol withdrawal safely in the community with the support of a primary care provider. This program will provide an overview of key elements and safety considerations of ambulatory alcohol withdrawal management programs. Consideration also will be given to the risk of other drugs including opioids in alcohol withdrawal management.</p> <p>Nicholas Piotrowski, MD, FASAM</p>
11:30 – 12:45	Lunch and Reflections	Recovery Reflections

12:45 – 1:45	PM Keynote	<p>Contingency Management: Experiences with Implementation</p> <p>Contingency Management (CM) is an evidence-based behavioral intervention using positive reinforcements to help people change their substance use patterns. CM has shown efficacy in reducing the use of a range of substances, including stimulants (cocaine and methamphetamine), alcohol, opioids, marijuana, and nicotine. Dr. Baldwin will: examine the principles of and evidence in support of contingency management as an effective treatment for a range of substance use disorders; highlight an example of CM in the treatment of stimulant use disorders specifically; discuss the basics of CM implementation, along with challenges of implementation.</p> <p>Mariella Baldwin, MD, MPH, Boston Chobanian & Avedisian School of Medicine</p>
1:45 – 1:55	transition	
1:55- 2:55	Workshop A2	<p>Implementing Peer Recovery as Part of the Clinical Team</p> <p>The integration of a peer support role within SUD treatment programs can have a profound positive effect on team dynamics and patient outcomes. In this session, we'll discuss peer support model fidelity, role clarity, and strategies to successfully integrate the role on multidisciplinary teams, including supervision and communication recommendations.</p> <p>Amanda Thompson</p>
	Workshop B2	<p>Treating Adolescents with Substance Use Disorders in Maine</p> <p>Join Deborah Hagler, MD, and Jonathan Fanburg, MD, as they discuss an overview of what is currently happening regarding adolescent Substance Use Disorders (SUD) screening, prevention, and treatment in Maine, things to consider as an adult provider treating adolescents, and challenges that are specific to treating adolescents with a SUD in Maine (attention will be given to treatment of adolescents using opioids). There will be time at the end to ask questions and share challenges you might be facing when it comes to treating adolescents.</p> <p>Dr. Deborah Hagler, Jonathan Fanburg, MD</p>

	Workshop C2	<p>Enhancing Access to Extended-Release Buprenorphine for Patients with Opioid Use Disorder (Opioid CAC Guidance Doc)</p> <p>Come learn how to utilize extended-release buprenorphine (XRB) when caring for patients with OUD. We will discuss clinical indications including XRB dosing and administration, XRB operational considerations including REMS certification as well as ordering, storing, and billing for the medication. Finally, we will discuss Mainecare’s XRB clinical criteria and related suggested workflows.</p> <p>Alane O’Connor, DNP, Kristen Silvia, MD, Anne Marie Toderico, PharmD</p>
2:55 – 3:05	Transition	
3:05 – 4:05	Video and Discussion	<p>What We Do Matters: Addressing Stigma in Health Care Towards People Who Use Substances</p> <p>This session will feature a documentary-style video to reveal the expressions and impact of stigma towards people with substance use disorders when they seek healthcare. A brief discussion will follow the video to promote further processing of the material presented.</p> <p>Kristen Silvia, MD</p>
4:05 – 4:10	Evaluation & Close	Closure